While COVID-19-related travel restrictions forced many regulators to explore virtual inspections to check ongoing compliance at drug manufacturing sites, there is general consensus that such assessments will continue being used to varying degrees even after the pandemic ends.
Drug companies have therefore suggested that the global inspectorate body, the Pharmaceutical Inspection Cooperation Scheme (PIC/S), should take steps to facilitate better understanding of all inspection tools, including for virtual...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?